ocrelizumab,interferon beta-1a
biogen,roche
['opera i,(-opera ii)', 'multiple sclerosis', 'ocrelizumab', 'genentech']
a subgroup analysis of the opera i/ii trials with over 9 years of follow-up with #ocrelizumab showed no evidence of disease activity in a high portion of treatment-naive patients with early relapsing multiple sclerosis. #aanam view: 
Delivering healthcare professionals treating neurological diseases quality and relevant information to help achieve the best patient care possible. #MindMoments